



Tasmanian
Government

Poisons Act 1971
Poisons Regulations 2018
Regulations 21 and 46

ELECTRONIC PRESCRIBING OF SCHEDULE 8 AND 4 MEDICATIONS

Approval No. R21-46/230124

I, Peter Boyles, Chief Pharmacist of the Department of Health and delegate of the Secretary for the purposes of Regulations 21 and 46 of the *Poisons Regulations 2018*, hereby grant approval for

Communicare
Version 22.1,
Conformance ID: Communicare|V22.1
(supplied by Telstra Health Pty Ltd ABN 38 163 077 236)

as an electronic prescription system in Tasmania.

The following conditions shall apply:

1. This approval is subject to the terms of the application contained within **Appendix I** seeking approval of **Communicare** for electronic transmission of prescriptions in **Tasmania**. Changes to obligations agreed to under the documentation included in **Appendix I** that impact upon the integrity of **Communicare – Version 22.1** for the purposes of electronic prescribing will result in this approval being revoked.
2. This approval is subject to **Communicare** remaining on the Australian Digital Health Agency (ADHA) Electronic Prescribing Register of Conformance. Changes to the Conformance Assessment Scheme (CAS) version, Conformance Profile version, or Conformance ID listing on the ADHA Electronic Prescribing Register of Conformance that impact upon **Communicare – Version 22.1** for the purposes of electronic prescribing will result in this approval being revoked.
3. This approval applies only to **Communicare – Version 22.1** detailed above for operation in **Tasmania**.
4. This approval is based upon **Communicare – Version 22.1** which has been assessed as meeting an adequate standard with respect to authentication (login), authorisation (signing), security, record keeping (storage of data), reporting and auditability.
5. Any subsequent version of **Communicare** must maintain as a minimum the current approved standards noted in condition 4.
6. **Communicare** maintains all other requirements detailed in the *Poisons Regulations 2018* with respect to supply, prescribing, and recording of Schedule 4 and Schedule 8 medications.

7. **Telstra Health Pty Ltd** to ensure Pharmaceutical Services Branch is provided detailed information in regard to updates (with appropriate user manual and release notes) of any subsequent versions of **Communicare**.
8. All records or documentation relating to prescribed substances must be retained for a minimum of TWO years except where specific requirement is stated.
9. All users of the system will complete an appropriate training course prior to their registration for use of the system.
10. **Telstra Health Pty Ltd** must make a copy of this approval available to users of the **Communicare**.

Dated this 24th day of January 2023



Peter Boyles
Chief Pharmacist

**Delegate for the purposes of
Regulation 21 and 46**

Appendix I

1. ***Application for Approval of Electronically Transmitted Prescription Systems for Communicare by Telstra Health Pty Ltd.***
2. **Copy of the Australian Digital Health Agency (ADHA) Electronic Prescribing Register of Conformance as at 12 January 2023.**